MOORESVILLE, N.C., Jan. 5, 2021 /PRNewswire/ -- Biohaven
Pharmaceuticals (NYSE:BHVN) announced today that
Nurtec® ODT (rimegepant) will be the primary
sponsor on the #51 Ligier JS P217 entry into the LMP2 class of
the 2021 24 Hours of Daytona. Biohaven joins Eurasia Motorsports
and BAM Motorsports Management as the primary partner for the
premier event. The 24-hour sports car endurance
race is held annually at Daytona International
Speedway in Daytona Beach, Florida, and is the first major automobile
race of the year. Former Daytona 500 Champion Austin Dillon, and 2019-2020 Asian Le Mans
Series Champion, Cody Ware, will
join the team as drivers for the race.
Rick Ware, former driver and
current team owner commented, "We are really excited to join the
field for the 24 Hours of Daytona this year. This is just another
step in the storied history of this organization, and we are hoping
for a great run at the end of next month."
The 24 Hours of Daytona is run on a 3.56-mile
(5.73 km) combined road course, utilizing portions of
the NASCAR tri-oval and an infield road course. Since its
inception, it has been held on the last weekend of January or first
weekend of February as part of Speedweeks, and is the first
race of the season for the WeatherTech SportsCar Championship.
The schedule of events includes the Roar Before the Rolex 24,
January 22-24; BMW Endurance
Challenge, January 29; and Rolex 24
At Daytona, January 30-31.
Vlad Coric, MD, Chief Executive
Officer of Biohaven stated, "Speed and endurance are two words that
describe the rapid onset of action and lasting effect when patients
consider treatment options for relief from their migraine attacks.
Being a part of the 24 Hours of Daytona is another first for us as
we continue to support innovative programs to drive awareness of
migraine disease and the importance of acute treatment."
Nearly 40 million people in the U.S. suffer from migraine
and the World Health Organization classifies migraine as one of the
10 most disabling medical illnesses. Migraine is
characterized by debilitating attacks lasting four to 72 hours with
multiple symptoms, including pulsating headaches of moderate to
severe pain intensity that can be associated with nausea or
vomiting, and/or sensitivity to sound (phonophobia) and sensitivity
to light (photophobia).
Nurtec ODT was approved by the U.S. Food and Drug
Administration (FDA) for the acute treatment of migraine in
February 2020 and is the first and
only CGRP receptor antagonist available in an orally disintegrating
tablet (ODT). A single dose of Nurtec ODT has been shown to
get people with migraine back to normal functioning within 60
minutes and have lasting effects for up to 48 hours.
"I am excited to be back behind the wheel of a Ligier LMP2 car,"
commented Cody Ware. "We had a lot
of success overseas in the Asian Le Mans Series, and created some
great relationships with other teams, like Eurasia Motorsports. I
can't wait to co-pilot the No. 51 Nurtec ODT car in the 24 Hours of
Daytona at Daytona International Speedway in January."
"My family and I have had a lot of special moments at Daytona
International Speedway so I'm thrilled to be able to add to those
memories with my first sports car endurance race in the 24 Hours of
Daytona," said Austin Dillon, the
2018 Daytona 500 Champion and a fulltime driver in the NASCAR Cup
Series for Richard Childress Racing. "Thank you to Rick Ware and everyone on the Nurtec ODT team
for the opportunity to get my Daytona Speedweeks started early this
year. I'm looking forward to the solid competition in the
WeatherTech SportsCar Championship and doing some road course
racing this January."
For additional information on Nurtec ODT,
visit www.nurtec.com. Follow Rick Ware Racing, by
visiting www.wareracing.com, and be sure to follow along on
social media
(Facebook, Twitter and/or Instagram).
About Rick Ware Racing
With a rich and extensive
history, Rick Ware Racing has been part of the racing fabric in the
USA for over 30 years. The team
has recently competed in both Prototypes and the NASCAR Cup Series.
The team most recently claimed the 2020 Asian Le Mans Series Am
Championship.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a
portfolio of innovative, best-in-class therapies to improve the
lives of patients with debilitating neurological and
neuropsychiatric diseases, including rare disorders. Biohaven's
neuroinnovation portfolio includes FDA-approved NURTEC® ODT
(rimegepant) for the acute treatment of migraine and a broad
pipeline of late-stage product candidates across three distinct
mechanistic platforms: CGRP receptor antagonism for the acute and
preventive treatment of migraine; glutamate modulation for
obsessive-compulsive disorder, Alzheimer's disease, and
spinocerebellar ataxia; and MPO inhibition for multiple system
atrophy and amyotrophic lateral sclerosis. More information about
Biohaven is available at www.biohavenpharma.com.
About NURTEC ODT
NURTEC® ODT (rimegepant) is the first and
only calcitonin gene-related peptide (CGRP) receptor antagonist
available in a quick-dissolve ODT formulation that is approved by
the U.S. Food and Drug Administration (FDA) for the acute
treatment of migraine in adults. The activity of the neuropeptide
CGRP is thought to play a causal role in migraine pathophysiology.
NURTEC ODT is a CGRP receptor antagonist that works by reversibly
blocking CGRP receptors, thereby inhibiting the biologic activity
of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75
mg, taken as needed, up to once daily. For more information about
NURTEC ODT, visit www.nurtec.com.
Indication
NURTEC® ODT (rimegepant) is indicated for
the acute treatment of migraine with or without aura in adults.
Limitations of Use
NURTEC ODT is not indicated for the preventive treatment of
migraine.
Important Safety Information
Contraindications: Hypersensitivity to NURTEC ODT or
any of its components.
Warnings and Precautions: If a serious
hypersensitivity reaction occurs, discontinue NURTEC ODT and
initiate appropriate therapy. Serious hypersensitivity
reactions have included dyspnea and rash, and can occur days after
administration.
Adverse Reactions: The most common adverse reaction
was nausea (2% in patients who received NURTEC ODT compared to 0.4%
in patients who received placebo). Hypersensitivity, including
dyspnea and rash, occurred in less than 1% of patients treated with
NURTEC ODT.
Drug Interactions: Avoid concomitant administration
of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate
inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose
of NURTEC ODT within 48 hours when it is administered with moderate
inhibitors of CYP3A4.
Use in Specific Populations:
Pregnant/breast feeding: It is not known if NURTEC ODT can harm an
unborn baby or if it passes into breast milk.
Hepatic impairment: Avoid use of NURTEC ODT in persons with severe
hepatic impairment.
Renal impairment: Avoid use in patients with end-stage renal
disease.
Please click here for full Prescribing
Information.
You are encouraged to report side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088 or report side effects to Biohaven at
1-833-4Nurtec.
Please click here for full Prescribing
Information and Patient Information.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland
DAC.
Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
Rick Ware Racing Contact:
Kate Fegley
Kate@K1Marketing.biz
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohavens-nurtec-odt-partners-with-rick-ware-racing-for-24-hours-of-daytona-entry-301201140.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.